ENGN
enGene HoldingsยทNASDAQ
--
--(--)
--
--(--)
ENGN Profile
Engene Holdings Inc.
A clinical-stage biotechnology company focused on non-viral gene therapies
4868 Rue Levy
Suite 220
Saint-Laurent
QC
Canada H4R 2P1
--
EnGene Holdings Inc., was registered under the federal laws of Canada as 14963148 Canada Inc., on April 24, 2023, and changed its name to enGene Holdings Inc., on May 9, 2023. The company is a clinical-stage biotechnology company that brings genetic medicine into the mainstream by delivering therapeutic drugs to mucosal tissues and other organs, with the goal of creating new approaches to address diseases with high clinical needs, starting with non-muscle invasive bladder cancer (NMIBC). The company is developing non-viral gene therapies based on its novel and proprietary dual-derived chitosan or "DDX" gene delivery platform, which allows direct localized delivery of multiple gene cargoes to mucosal tissues and other organs.
